# A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis

> **NCT03119649** · PHASE2 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 59 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** GLPG2222 50 mg
- **DRUG:** GLPG2222 100 mg
- **DRUG:** Placebo
- **DRUG:** GLPG2222 200 mg
- **DRUG:** GLPG2222 400 mg

## Key facts

- **NCT ID:** NCT03119649
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-18
- **Primary completion:** 2017-10-19
- **Final completion:** 2017-10-19
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2018-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03119649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03119649, "A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03119649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*